Elanco Animal Health Incorporated (ELAN) vs Neurocrine Biosciences, Inc. (NBIX)
- Elanco Animal Health Incorporated ELAN 23.55 +0.04%
- Neurocrine Biosciences, Inc. NBIX 135.71 −0.91%
Elanco Animal Health Incorporated and Neurocrine Biosciences, Inc. are both Drug Manufacturers Specialty & Generic companies. Neurocrine Biosciences, Inc. is the larger, with a market value of $13.9B against $11.8B — 1.2× the size. Elanco Animal Health Incorporated has negative trailing earnings, so its P/E is not meaningful; Neurocrine Biosciences, Inc. trades at 19.2×. Neurocrine Biosciences, Inc. grew revenue faster over the last twelve months: 34.4% against 12.0%. Neurocrine Biosciences, Inc. has the higher net margin (20.9% vs −3.96%) and the higher return on invested capital (15.0% vs 0.51%). Across the 21 metrics below, Neurocrine Biosciences, Inc. leads on 17 and Elanco Animal Health Incorporated on 4.
Valuation
Profitability
| Metric | ELAN | NBIX | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 55.36% | 97.94% | 53.94% |
| Operating margin | 1.61% | 23.56% | 0.00% |
| Net margin | (3.96%) | 20.91% | 0.00% |
| Free cash flow margin | 7.55% | 25.80% | 0.00% |
| Return on equity | (2.98%) | 22.09% | (0.40%) |
| Return on assets | (1.46%) | 15.26% | (3.32%) |
| Return on invested capital | 0.51% | 15.04% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack